Regorafenib Versus Placebo to Treat Cholangiocarcinoma
NCT02162914
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
66
Enrollment
OTHER
Sponsor class
Conditions
Cholangiocarcinoma
Interventions
DRUG:
Regorafenib/active
DRUG:
Regorafenib/placebo
Sponsor
Erasme University Hospital